Lindbrook Capital’s Nuvation Bio NUVB Stock Holding History

Lindbrook Capital’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$130	Buy	+74	New	+$168	﹤0.01%	2744
2024 Q4	–	Sell	-154	Closed	-$353	–	2870
2024 Q3	$353	Buy	+154	New	+$470	﹤0.01%	2738
2023 Q3	–	Sell	-941	Closed	-$1.69K	–	2784
2023 Q2	$1.69K	Buy	941 +777	+474%	+$1.32K	﹤0.01%	2214
2023 Q1	$272	Sell	164 -2,720	-94%	-$5.51K	﹤0.01%	2682
2022 Q4	$5.54K	Buy	2,884 +2,053	+247%	+$4.15K	﹤0.01%	1764
2022 Q3	$2K	Buy	+831	New	+$2.37K	﹤0.01%	2105

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Lindbrook Capital's NUVB Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Nuvation Bio (NUVB) in Q1 2025: 74 shares worth $130. The stake represents ﹤0.01% of the portfolio and ranks #2744 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in NUVB as recently as Q3 2024.

Lindbrook Capital first reported a position in NUVB in Q3 2022 and has held it in 6 quarters since. The position peaked at $5.54K in Q4 2022. 161 funds tracked by Wall St. Rank hold NUVB as of Q1 2025.

Lindbrook Capital held 74 shares of Nuvation Bio worth $130 as of Q1 2025.
Nuvation Bio was a new Lindbrook Capital position in Q1 2025.
Nuvation Bio made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2744 holding.
Lindbrook Capital first reported a position in Nuvation Bio in Q3 2022 and has held it in 6 quarters since.
Lindbrook Capital's Nuvation Bio position peaked at $5.54K in Q4 2022.
161 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.